Results from a new study are providing new insights into the therapeutic potential of bacteriophage (phage) therapy for treating diseases like cystic fibrosis (CF).
Read more …New insights into phage therapy design
Scientists uncover why cancer patients with ARID1A gene mutations are more likely to respond to immunotherapy, discovering ARID1A mutations invite cancer-fighting immune cells into tumors by triggering an antiviral-like response. Their findings could help improve cancer care and drug development for many cancer types, including endometrial, ovarian, colon, gastric, liver, and pancreatic cancers.
Read more …This time, it's personal: Enhancing patient response to cancer immunotherapy
At present, there is no specific active substance against hepatitis E. As the disease kills 70,000 people every year, researchers are actively searching for one. A team may have found what they're looking for. The researchers showed that the compound K11777 prevents host cells from helping the virus out of its shell by cleaving the viral capsid. This means it can no longer infect cells.
Read more …An active agent against hepatitis E